POC(Point-Of-Care) 진단 기기 시장 예측(-2034년) : 제품 유형, 검체 유형, 기술, 용도, 최종사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Point-of-Care Diagnostic Devices Market is accounted for $48 billion in 2026 and is expected to reach $85 billion by 2034 growing at a CAGR of 7.5% during the forecast period. Point-of-Care Diagnostic Devices are portable medical tools used to perform diagnostic tests at or near the site of patient care. These devices provide rapid results for conditions such as infections, blood glucose levels, cardiac markers, and more, enabling immediate clinical decisions. They reduce the need for centralized laboratory testing and improve efficiency in healthcare delivery. Widely used in hospitals, clinics, and home settings, point-of-care devices support early diagnosis, timely treatment, and improved patient outcomes, particularly in emergency and remote care environments.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

Rising cases of diabetes, cardiovascular disorders, and infectious diseases have created urgent demand for rapid, accurate, and accessible diagnostic solutions. Point-of-care devices enable immediate testing and results, supporting timely clinical decisions and reducing hospital visits. Their portability and ease of use make them suitable for both clinical and home settings. Healthcare providers are increasingly adopting these devices to improve patient outcomes and reduce the burden on centralized laboratories. The growing global burden of chronic illnesses is expected to sustain strong demand for point-of-care diagnostics.

Restraint:

Regulatory approval challenges

Stringent requirements for clinical validation, safety, and accuracy often delay product launches. Manufacturers face complex approval processes across different regions, which increases costs and slow global expansion. Smaller companies, in particular, struggle to navigate these regulatory hurdles, limiting innovation. Healthcare providers may hesitate to adopt new devices until they receive full regulatory clearance, further slowing uptake. While regulatory bodies aim to ensure patient safety, the lengthy approval timelines remain a barrier to rapid commercialization.

Opportunity:

Integration with digital health platforms

Linking devices with mobile apps, electronic health records, and telehealth platforms enhances data accessibility and patient monitoring. Physicians can remotely track patient results, enabling proactive interventions and personalized treatment plans. Patients benefit from improved convenience and engagement, as results can be shared instantly with healthcare providers. This integration also supports population health management and chronic disease monitoring at scale. Companies are increasingly investing in connected diagnostics to align with digital health trends. As healthcare systems embrace digital-first models, integration opportunities are expected to drive significant growth.

Threat:

Pricing pressure from low-cost devices

Many local manufacturers in emerging economies offer affordable point-of-care solutions, challenging established players. Price-sensitive markets often prioritize cost over advanced features, limiting margins for premium products. This competitive environment forces companies to balance innovation with affordability. Healthcare providers may opt for cheaper alternatives, even if they lack advanced connectivity or analytics. The threat of commoditization is particularly strong in segments such as glucose monitoring and rapid infectious disease tests.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of point-of-care diagnostic devices. Rapid testing became essential for managing infection spread, driving unprecedented demand for portable diagnostic solutions. Governments and healthcare systems invested heavily in point-of-care testing infrastructure during the crisis. The pandemic also highlighted the importance of decentralized diagnostics, reducing reliance on centralized laboratories. Post-pandemic, the momentum continues as healthcare providers recognize the value of rapid diagnostics for chronic disease management and emergency care. Manufacturers are leveraging lessons from COVID-19 to expand product portfolios and strengthen supply chains.

The immunoassays segment is expected to be the largest during the forecast period

The immunoassays segment is expected to account for the largest market share during the forecast period as the increasing prevalence of chronic diseases has heightened demand for rapid and accurate biomarker detection. Immunoassays are widely used for diagnosing infectious diseases, monitoring chronic conditions, and detecting cancer markers. Their versatility and reliability make them a cornerstone of point-of-care diagnostics. Advances in microfluidics and portable platforms are enhancing the efficiency of immunoassays. Hospitals, clinics, and home care settings increasingly rely on these tests for immediate decision-making. The segment benefits from strong demand across both developed and emerging markets.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate due to the increasing prevalence of chronic diseases, which has driven demand for convenient, at-home diagnostic solutions. Patients with diabetes, cardiovascular disorders, and respiratory conditions increasingly rely on point-of-care devices for self-monitoring. Home-based diagnostics reduce hospital visits, improve adherence, and empower patients to manage their health. The segment benefits from growing adoption of connected devices that integrate with mobile apps and telehealth platforms. Rising healthcare costs and aging populations further support the shift toward home care. Manufacturers are focusing on user-friendly, portable devices tailored for home use.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and the increasing prevalence of chronic diseases across the population. The U.S. leads in adoption of point-of-care diagnostics, supported by strong reimbursement frameworks and regulatory approvals. Major players in the market are headquartered in the region, driving innovation and commercialization. High incidence of diabetes, cardiovascular disorders, and cancer fuels demand for rapid diagnostics. The region also benefits from strong integration of digital health platforms with point-of-care devices. Ongoing investments in R&D and clinical trials further strengthen market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare digitization and the increasing prevalence of chronic diseases in emerging economies. Countries such as China, India, and Southeast Asia are witnessing rising demand for affordable and accessible diagnostics. Governments are investing in healthcare infrastructure and promoting decentralized testing to improve equity. Local manufacturers are offering cost-effective solutions, boosting adoption in price-sensitive markets. Growing smartphone penetration and telehealth initiatives enhance integration of point-of-care devices with digital platforms. Rising awareness of preventive healthcare further supports market expansion.

Key players in the market

Some of the key players in Point-of-Care Diagnostic Devices Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, QuidelOrtho Corporation, PerkinElmer Inc., Sekisui Diagnostics, Trinity Biotech, Arkray Inc., SD Biosensor Inc., Werfen, Hologic Inc. and Fujifilm Holdings Corporation.

Key Developments:

In March 2026, Arkray launched a portable HbA1c analyzer for diabetes management in outpatient clinics. The device provides immediate results, enabling clinicians to adjust treatment plans during patient visits. Arkray's innovation reinforces its focus on chronic disease management through point-of-care solutions.

In September 2025, Bio-Rad introduced a compact immunoassay analyzer for decentralized oncology testing. The system supports biomarker-guided therapy decisions, offering clinicians rapid results outside central labs. Bio-Rad's innovation reflects its focus on precision diagnostics and expanding access to personalized medicine tools.

In June 2025, Sekisui Diagnostics launched a rapid point-of-care test for C-reactive protein (CRP), supporting infection and inflammation management. The device offers results in under five minutes, aiding primary care decision-making. Sekisui's expansion into portable immunoassays strengthens its role in frontline diagnostics.

Product Types Covered:

• Glucose Monitoring Devices
• Infectious Disease Testing Devices
• Cardiac Marker Testing Devices
• Blood Gas & Electrolyte Analyzers
• Other Product Types

Sample Types Covered:

• Blood
• Urine
• Saliva
• Nasal/Throat Swabs
• Other Sample Types

Technologies Covered:

• Lateral Flow Assays
• Immunoassays
• Molecular Diagnostics
• Microfluidics
• Biosensors
• Other Technologies

Applications Covered:

• Diabetes Testing
• Cardiovascular Diseases
• Oncology Testing
• Pregnancy & Fertility Testing
• Other Applications

End Users Covered:

• Hospitals
• Clinics
• Diagnostic Centers
• Home Care Settings
• Other End Users

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Point-of-Care Diagnostic Devices Market, By Product Type

• 5.1 Glucose Monitoring Devices
• 5.2 Infectious Disease Testing Devices
• 5.3 Cardiac Marker Testing Devices
• 5.4 Blood Gas & Electrolyte Analyzers
• 5.5 Other Product Types

6 Global Point-of-Care Diagnostic Devices Market, By Sample Type

• 6.1 Blood
• 6.2 Urine
• 6.3 Saliva
• 6.4 Nasal/Throat Swabs
• 6.5 Other Sample Types

7 Global Point-of-Care Diagnostic Devices Market, By Technology

• 7.1 Lateral Flow Assays
• 7.2 Immunoassays
• 7.3 Molecular Diagnostics
• 7.4 Microfluidics
• 7.5 Biosensors
• 7.6 Other Technologies

8 Global Point-of-Care Diagnostic Devices Market, By Application

• 8.1 Diabetes Testing
• 8.2 Cardiovascular Diseases
• 8.3 Oncology Testing
• 8.4 Pregnancy & Fertility Testing
• 8.5 Other Applications

9 Global Point-of-Care Diagnostic Devices Market, By End User

• 9.1 Hospitals
• 9.2 Clinics
• 9.3 Diagnostic Centers
• 9.4 Home Care Settings
• 9.5 Other End Users

10 Global Point-of-Care Diagnostic Devices Market, By Geography

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
  • 10.1.3 Mexico
• 10.2 Europe
  • 10.2.1 United Kingdom
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Netherlands
  • 10.2.7 Belgium
  • 10.2.8 Sweden
  • 10.2.9 Switzerland
  • 10.2.10 Poland
  • 10.2.11 Rest of Europe
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Australia
  • 10.3.6 Indonesia
  • 10.3.7 Thailand
  • 10.3.8 Malaysia
  • 10.3.9 Singapore
  • 10.3.10 Vietnam
  • 10.3.11 Rest of Asia Pacific
• 10.4 South America
  • 10.4.1 Brazil
  • 10.4.2 Argentina
  • 10.4.3 Colombia
  • 10.4.4 Chile
  • 10.4.5 Peru
  • 10.4.6 Rest of South America
• 10.5 Rest of the World (RoW)
  • 10.5.1 Middle East
    • 10.5.1.1 Saudi Arabia
    • 10.5.1.2 United Arab Emirates
    • 10.5.1.3 Qatar
    • 10.5.1.4 Israel
    • 10.5.1.5 Rest of Middle East
  • 10.5.2 Africa
    • 10.5.2.1 South Africa
    • 10.5.2.2 Egypt
    • 10.5.2.3 Morocco
    • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

• 11.1 Industry Value Network and Supply Chain Assessment
• 11.2 White-Space and Opportunity Mapping
• 11.3 Product Evolution and Market Life Cycle Analysis
• 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

• 12.1 Mergers and Acquisitions
• 12.2 Partnerships, Alliances, and Joint Ventures
• 12.3 New Product Launches and Certifications
• 12.4 Capacity Expansion and Investments
• 12.5 Other Strategic Initiatives

13 Company Profiles

• 13.1 Abbott Laboratories
• 13.2 Roche Diagnostics
• 13.3 Siemens Healthineers
• 13.4 Danaher Corporation
• 13.5 Becton Dickinson and Company
• 13.6 Bio-Rad Laboratories
• 13.7 QuidelOrtho Corporation
• 13.8 PerkinElmer Inc.
• 13.9 Sekisui Diagnostics
• 13.10 Trinity Biotech
• 13.11 Arkray Inc.
• 13.12 SD Biosensor Inc.
• 13.13 Werfen
• 13.14 Hologic Inc.
• 13.15 Fujifilm Holdings Corporation